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Background: Studies by comparative
genomic hybridization (CGH) have
shown that chromosomal region 17q23
is amplified in up to 20% of primary
breast cancers. We used microarray
analyses to measure the expression lev-
els of genes in this region and to explore
their prognostic importance. Methods:
A microarray that contained 4209
complementary DNA (cDNA) clones
was used to identify genes that are
overexpressed in the MCF-7 breast
cancer cell line as compared with nor-
mal mammary tissue. Fluorescence in
situ hybridization was used to analyze
the copy number of one overexpressed
gene, ribosomal protein S6 kinase
(S6K), and to localize it to the 17q23
region. Northern and western blot
analyses were used to measure S6K
gene and protein expression, and an en-
zymatic assay was used to measure S6K
activity. Tumor tissue microarray
analysis was used to study amplifica-
tion of S6K and the HER-2 oncogene,
another 17q-linked gene, and the rela-
tionship between amplification and
prognosis was analyzed. The Kaplan–
Meier method was used for data analy-
sis, and the log-rank test was used for
statistical analysis. All P values are
two-sided. Results: S6K was amplified
and highly overexpressed in MCF-7
cells relative to normal mammary epi-
thelium, and protein expression and en-
zyme activity were increased. S6K was
amplified in 59 (8.8%) of 668 primary
breast tumors, and a statistically sig-
nificant association between amplifica-
tion and poor prognosis (P = .0021) was
observed. Amplification of both S6K
and HER-2 implied particularly poor
survival (P = .0001). Conclusions: The
combination of CGH information with
cDNA and tissue microarray analyses
can be used to identify amplified and
overexpressed genes and to evaluate
the clinical implications of such genes
and genomic rearrangements. S6K is
likely to be one of the genes at 17q23
that is amplified during oncogenesis
and may adversely affect the prognosis
of patients with this amplification.
[J Natl Cancer Inst 2000;92:1252–9]
Large-scale gene expression surveys,
such as complementary DNA (cDNA)
microarrays (1), serial analysis of gene
expression (2), or high-throughput cDNA
sequencing, have made it possible to
screen for the expression levels of thou-
sands of genes in a tumor. In a typical
cDNA microarray experiment, up to
10 000 genes are simultaneously analyzed
in a parallel fashion, revealing hundreds
of genes that are differentially expressed
relative to those of a control tissue. Ana-
lyzing and interpreting this genomic-scale
information to pinpoint alterations in spe-
cific genes that could be utilized for de-
veloping clinical applications, such as
finding targets with potential diagnostic,
prognostic, or therapeutic applications,
have become increasingly important chal-
lenges. To rank the large number of tar-
gets for further study, it is important to
separate primary genetic alterations from
secondary, downstream changes in gene
expression.
Gene amplification is an important
mechanism for increasing expression of
critical genes involved in the initiation
and progression of cancer. Indeed, in
breast cancer, a number of important on-
cogenes have already been found to be
activated by DNA amplification. These
oncogenes include HER-2 (at chromo-
some 17q12), C-MYC (at 8q24), PRAD1/
CYCLIN D (at 11q13), FGFR-1 (at
8p12), and FGFR-2 (at 10q24) (3). Fur-
thermore, studies by comparative geno-
mic hybridization (CGH) (4–7) and chro-
mosome microdissection (8) have
revealed that numerous other chromo-
somal regions frequently undergo ampli-
fication in breast cancer. Focused studies
of the amplification region at 20q12–
20q13 have implicated a number of over-
expressed genes with putative oncogenic
potential, such as AIB1, BTAK, CAS-1,
and ZNF217 (9–12), indicating that mul-
tiple genes may be induced in a given
amplification region.
Our laboratory is using cDNA micro-
array analyses of breast cancer cell lines
that harbor high-level DNA amplifica-
tions to explore the consequences of these
multiple genomic DNA amplifications on
the pattern of gene expression. This strat-
egy could highlight genes that are targets
for the clonal selection process that leads
to DNA amplification. Of particular inter-
est are the consequences of genomic re-
arrangements at 17q23, a locus that has
been shown by CGH to be amplified in up
to 20% of primary breast cancers (4–7).
We showed that at least two separate re-
gions at 17q23 undergo high-level ampli-
fication in breast cancer (13).
Here we report the results of a cDNA
microarray analysis of expression levels
of 4209 clones in the MCF-7 breast can-
cer cell line. Tissue microarray (14)
analysis of 668 primary breast cancers
was used to determine the in vivo impor-
tance of the amplified and overexpressed
genes that we discovered in the cell line
and to explore the relationship between
gene amplification and patient survival.
METHODS
Cell Lines
Breast cancer cell lines BT-474, HBL-100, MCF-
7, MDA-436, and ZR-75-1wt were obtained from
the American Type Culture Collection (Manassas,
VA), KPL-1 from the German Collection of Micro-
organisms and Cell Cultures (Braunschweig, Ger-
many), and Sum-52 from S. P. Ethier (University of
Michigan, Ann Arbor).
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Construction of Primary Breast
Tumor Microarrays
Two groups of primary breast cancer tissue speci-
mens were obtained from the Institute of Pathology,
University of Basel, Switzerland, for the construc-
tion of tissue microarrays. The first group consisted
of 372 ethanol-fixed primary breast cancer speci-
mens [described in (14)]. The second group con-
sisted of 612 formalin-fixed, paraffin-embedded pri-
mary breast cancer specimens from the years 1985–
1995 obtained from patients with clinicopathologic
information that included an average of 5.4 years of
follow-up. All specimens were anonymous, archival
tissue specimens. The use of these specimens for
retrospective analyses was approved by the Ethics
Committee of the University of Basel, and their use
for tissue microarray analysis was approved by the
National Institutes of Health Institutional Review
Board.
The tumor samples were reviewed by one pa-
thologist (J. Torhorst) and included 73.3% ductal,
13.6% lobular, 3.0% medullary, 2.6% mucinous,
1.5% cribriform, 1.4% tubular, and 1.1% papillary
carcinomas; 1.9% ductal carcinoma in situ; and
1.7% of other rare histologic subtypes. The grade
distribution (15) was 24% grade 1, 40% grade 2, and
36% grade 3. The postoperative tumor–node–
metastasis (pT) stage (16) was 32% pT1, 51% pT2,
7% pT3, and 10% pT4. The average age of the pa-
tients was 60 years (range  26–97 years); 50% of
these patients had lymph node-negative disease and
50% had lymph node-positive disease.
The tissue microarrays were constructed as de-
scribed previously (14). Briefly, a representative tu-
mor area was selected from hematoxylin–eosin-
stained sections of each tumor. The individual donor
tissue blocks and the corresponding histologic slides
were overlaid for tissue microarray sampling. A tis-
sue microarray instrument (Beecher Instruments,
Silver Spring, MD) was used to create holes in a
recipient paraffin block, to obtain cylindrical core
tissue biopsy samples with a diameter of 0.6 mm
from the donor paraffin blocks, and to transfer these
biopsy samples to the recipient block at defined ar-
ray positions. Multiple 5-m sections were cut from
the tissue microarray block by use of a microtome
with an adhesive-coated-tape sectioning system (In-
strumedics, Inc., Hackensack, NJ).
CGH Analysis of MCF-7
CGH was done as described previously (17).
Briefly, 400 ng of MCF-7 genomic DNA was fluo-
rescently labeled with SpectrumGreen–deoxyuridine
triphosphate (dUTP) (Vysis, Inc., Downers Grove,
IL) by the use of nick translation. Normal placental
DNA was fluorescently labeled in the same manner
with SpectrumOrange–dUTP (Vysis, Inc.). The la-
beled DNAs were hybridized to normal metaphase
chromosomes, and the chromosomes were counter-
stained with 4,6-diamidino-2-phenylindole (DAPI)
(Boehringer Mannheim Biochemicals, Indianapolis,
IN). The hybridizations were evaluated by use of a
Zeiss microscope (Carl Zeiss, Inc., Thornwood, NY)
and the Quips XL program (Vysis, Inc.). The fluo-
rescence intensities of MCF-7 DNA and placental
DNA were measured along chromosome 17, and
their ratios (DNA sequence copy number in MCF-7
cells/copy number in normal tissue) were computed.
The average copy number ratio from 10 chromo-
somes and the 95% confidence interval were calcu-
lated.
Construction of cDNA Microarray
A total of 4209 cDNA clones from the set of
15 289 IMAGE (i.e., Integrated Molecular Analysis
of Genomes and Their Expression) consortium
cDNA clones described earlier (18–20) were printed
onto glass slides as described previously (1). Radia-
tion hybrid-mapping information was available for
about 50% of them (21). The set included 88 house-
keeping genes that were used as controls in the nor-
malization of the data and 135 clones from chromo-
some 17, including eight clones from 17q23. Based
on the information in the radiation hybrid map (21),
this represents approximately 10% of all cDNAs
from this region.
Fluorescent cDNA Microarray
Analysis of MCF-7 Cells
Total RNA was extracted from MCF-7 cells by
use of the RNeasy kit (Qiagen, Inc., Valencia, CA).
The labeling and hybridization were done as de-
scribed previously (18,22). Briefly, 100–200 g of
total MCF-7 RNA was used as template to prepare
cDNA probes labeled with dUTP coupled to Cya-
nine5 (Cy5) fluorescent dye (Amersham Pharmacia
Biotech, Inc., Piscataway, NJ) by use of oligo(dT)-
primed polymerization by SuperScript II reverse
transcriptase (Life Technologies, Inc. [GIBCO
BRL], Gaithersburg, MD). Probes complementary
to normal mammary gland RNA (Clontech Labora-
tories, Inc., Palo Alto, CA) were prepared in the
same manner, except that the dUTP was coupled to
Cyanine3 (Cy3) fluorescent dye (Amersham Phar-
macia Biotech, Inc.). The labeled cDNAs were com-
bined with 8 g of polydeoxyadenylic acid (Amer-
sham Pharmacia Biotech, Inc.), 4 g of Escherichia
coli transfer RNA (Sigma Chemical Co., St. Louis,
MO), and 10 g Cot-1 DNA (Life Technologies,
Inc.) in 0.15% sodium dodecyl sulfate (SDS) and 3×
standard saline citrate (SSC) (i.e., 450 mM NaCl and
45 mM sodium citrate). The probe mixture was in-
cubated at 98 °C for 2 minutes and at 4 °C for 10
seconds and was applied onto the microarray slide.
Hybridization was carried out at 65 °C for 16 hours.
The slides were washed in 0.5× SSC (i.e., 75 mM
NaCl and 7.5 mM sodium citrate) and 0.01% SDS at
55 °C for 2 minutes each.
Analysis of cDNA Microarray Data
Fluorescence intensities at the targets were mea-
sured by use of a custom-designed laser confocal
microscope equipped with a scanning stage, appro-
priate excitation and emission filters, and a photo-
multiplier tube detector (18). Intensity data were in-
tegrated over 225-m2 pixels and recorded at 16
bits. The fluorescent images from the MCF-7 hy-
bridization and from the hybridization with normal
mammary tissue were scanned separately. The
MCF-7 image was assigned a red color and the ref-
erence image was assigned a green color to form a
pseudo-color image. In this image, spots that appear
in red correspond to genes overexpressed in MCF-7
cells, and those that are green correspond to genes
whose expression is lower in MCF-7 than in the
control sample (normal mammary tissue).
The results of the cDNA microarray experiments
were analyzed by use of the ArraySuite program
(developed at the National Human Genome Re-
search Institute, Bethesda, MD, by Y. Chen) based
on the IPLab Spectrum platform (23). The program
identified and segmented spots in the images corre-
sponding to the MCF-7 (red) and normal mammary
(green) cDNA hybridizations. After background
subtraction, average intensities at each spot in the
MCF-7 hybridization were divided by the average
intensity of the same spot in the normal mammary
hybridization. The ratios were normalized on the
basis of the distribution of ratios for the 88 house-
keeping genes (22). This ensured that the ratios ob-
tained were not affected by differential labeling or
hybridization efficiency of the two cDNAs, by the
quantity of the labeled cDNA in the hybridization
reaction, or by the photomultiplier voltage settings
during scanning. The ArraySuite program also al-
lows visualization of the image for each spot. For
this study, the spot images were displayed at the
chromosomal locations of the relevant clones to pro-
vide a visual comparison of DNA amplification sites
with chromosomal locations of overexpressed
genes. The chromosomal locations of the clones
came from radiation hybrid-mapping data available
in the human gene map (21). Radiation hybrid map-
ping is a method of physical mapping that uses the
frequencies of x-ray-induced DNA breakage to de-
duce distances between markers, which are ex-
pressed in centiRays (cR), the genetic map distance
that corresponds to an interval in the radiation hy-
brid map in which there is a 1% probability of x-ray-
induced DNA breakage.
Mapping and Copy Number Analysis
of Ribosomal Protein S6 Kinase by
Fluorescence In Situ Hybridization
A P1 artificial chromosome probe (clone 186o9)
specific for ribosomal protein S6 kinase (S6K) was
obtained by screening of a commercially available
library (Genome Systems, Inc., St. Louis, MO) by
the use of the polymerase chain reaction. The S6K
probe was fluorescently labeled with SpectrumOr-
ange–dUTP by use of random priming and was hy-
bridized to normal metaphase chromosomes to map
the S6K gene as described previously (13). The
SpectrumOrange-labeled S6K probe was also used
together with a SpectrumGreen fluorescently labeled
probe for the centromere of chromosome 17 for
copy number analysis by interphase fluorescence in
situ hybridization (FISH) as described previously
(13). The hybridizations were evaluated by use of a
Zeiss fluorescence microscope. Approximately 20
nonoverlapping nuclei with intact morphology
(evaluated by use of the DAPI counterstain) were
scored to determine the mean number of hybridiza-
tion signals for each probe. Amplification was mea-
sured by a comparison of the number of signals pro-
duced by use of the probe for S6K with the number
produced by use of the probe for the chromosome 17
centromere.
Tissue Microarray Analysis by FISH
For the tissue microarrays, the FISH protocol was
changed according to the type of tissue fixation
used. The ethanol-fixed tissue microarray was depa-
raffinized, denatured at 73 °C for 5 minutes in 2×
SSC (i.e., 300 mM NaCl and 30 mM sodium citrate)
containing 70% formamide, and dehydrated in an
ethanol series (70% , 80%, and 100%). The forma-
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lin-fixed tissue microarray was deparaffinized, im-
mersed in 0.2 N HCl, incubated in 1 M sodium thio-
cyanate solution at 80 °C for 30 minutes, and
immersed in a protease solution (0.5 mg/mL in 0.9%
NaCl; Vysis, Inc.) for 10 minutes at 37 °C. These
slides were then postfixed in 10% buffered formalin
(Sigma Chemical Co.), air-dried, denatured at 73 °C
for 5 minutes in 2× SSC containing 70% formamide,
dehydrated in an ethanol series, incubated in 4 g/
mL proteinase K (Boehringer Mannheim Biochemi-
cals) at 37 °C for 7 minutes, and dehydrated again as
above. Both ethanol-fixed and formalin-fixed slides
were hybridized with the SpectrumOrange-labeled
S6K-specific probe and the SpectrumGreen-labeled
chromosome 17 centromere probe overnight at
37 °C. An adjacent section from the tissue microar-
ray was hybridized with a SpectrumOrange-labeled
HER-2 probe (Vysis, Inc.). Specimens containing
tight clusters of signals or more than a threefold
increase in the number of S6K signals, as compared
with chromosome 17 centromere signals, in at least
10% of the tumor cells were considered to be am-
plified.
Our tissue microarrays comprised 984 tumor
samples. Analysis of S6K and HER-2 copy numbers
was uninformative in 316 and 374 cases, respec-
tively, because of missing or unrepresentative tumor
samples in the array section or failure of the analysis.
Northern Blot Analysis
Total RNA was extracted from breast cancer cell
lines by use of the RNeasy kit. RNA (10 g) was
subjected to electrophoresis through a 1 M formal-
dehyde–1% agarose gel and transferred onto a
Nytran membrane (Schleicher & Schuell, Inc.,
Keene, NH) by standard methods (24). The insert
from a sequence-verified cDNA clone (GenBank ac-
cession number H04661) representing the 3-end of
the S6K gene was 32P-labeled by random priming
(Prime-It; Stratagene Cloning Systems, La Jolla,
CA). The blot was prehybridized with 10 g/mL
boiled, sheared DNA (Research Genetics, Hunts-
ville, AL) for 1 hour at 68 °C in Express Hybridiza-
tion solution (Clontech Laboratories, Inc.). Hybrid-
ization was done in the prehybridization solution at
68 °C overnight. The blot was washed several times
with 1% SDS in 2× SSC at 65 °C and then in 0.5%
SDS in 0.1× SSC (i.e., 15 mM NaCl and 1.5 mM
sodium citrate) at 55 °C. Hybridized probe was de-
tected by autoradiography. After removal of bound
S6K probe, the membrane was rehybridized with a
probe for glyceraldehyde-3-phosphate dehydroge-
nase messenger RNA (mRNA) to confirm equal
loading among samples. The expression levels were
quantitated by use of the PhosphorImager (Molecu-
lar Dynamics, Sunnyvale, CA).
Western Blot Analysis
Breast cancer cell line monolayers were trypsin-
ized to yield a cell suspension and centrifuged at
200g for 8 minutes at room temperature. The pre-
cipitated cells were lysed in RIPA buffer (i.e., 1%
phosphate-buffered saline [PBS], 1% Nonidet P-40,
0.5% sodium deoxycholate, and 0.1% SDS) by re-
peated passage through a 21-gauge needle and cen-
trifuged at 10 000g for 10 minutes at 4 °C. Approxi-
mately 40 g of total protein was boiled in loading
buffer (Laemmli Sample Buffer; Bio-Rad Laborato-
ries, Hercules, CA) for 5 minutes, subjected to elec-
trophoresis through a 4%–12% polyacrylamide gra-
dient Tris-glycine gel (Novex, San Diego, CA),
along with Full-Range Rainbow Molecular Weight
Markers (Amersham Life Science, Little Chalfont,
Buckinghamshire, U.K.), and electroblotted onto a
nitrocellulose membrane (Novex). Detection of pro-
tein was by the BM Chemiluminescence Western
Blotting Kit (Mouse/Rabbit) (Boehringer Mannheim
Biochemicals). Briefly, the membrane was incu-
bated for 1 hour at room temperature in 1% blocking
solution (Boehringer Mannheim Biochemicals) and
for 1 hour at 4 °C in a solution of 4 g/mL primary
antibody (anti-p70S6k antibody; Santa Cruz Biotech-
nology, Inc., Santa Cruz, CA) in 0.5% blocking so-
lution. The membrane was washed two times for
10 minutes each in TBS–Tween® 20 (Boehringer
Mannheim Biochemicals) and then twice with 0.5%
blocking solution, incubated for 30 minutes at 4 °C
with peroxidase-labeled secondary antibody (mouse
anti-rabbit immunoglobulin G; Boehringer Mann-
heim Biochemicals), and then washed four times for
15 minutes each with large volumes of TBS–
Tween® 20. Signal detection was done according to
the manufacturer’s instructions. The membrane was
restained with anti-tubulin antibody to confirm equal
loading of samples.
Measurement of S6K Activity
Breast cancer cell line monolayers in 100-mm
dishes were washed once in PBS. The cells were
lysed directly on the dishes by incubation for 20
minutes in 1 mL of cold modified radioimmunopre-
cipitation assay buffer (i.e., 50 mM Tris–HCl
[pH.7.4], 1% Nonidet P-40, 0.25% sodium deoxy-
cholate, 150 mM NaCl, 1 mM ethylene glycol-bis(-
aminoethyl ether)-N,N,N,N-tetraacetic acid, 1 mM
phenylmethylsulfonyl fluoride, 1 mM Na3VO4, and
1 mM NaF) containing a protease inhibitor cocktail
(Complete Protease Inhibitor Cocktail) prepared ac-
cording to the manufacturer’s instructions (Boeh-
ringer Mannheim Biochemicals). The lysates were
passed repeatedly through a 21-gauge needle and
centrifuged at 10 000g for 10 minutes at 4 °C, and
the supernatant was collected. Approximately 200
g of protein was incubated overnight at 4 °C with
1 g of anti-p70S6k antibody. The immunocomplex
was absorbed to 50 L protein A–agarose (Life
Technologies, Inc.) by incubation for 3 hours at 4 °C
and washed four times with cold PBS. S6K enzyme
activity was assayed by use of the S6 Kinase Assay
Kit according to the recommendations of the manu-
facturer (Upstate Biotechnology, Lake Placid, NY).
Briefly, the agarose beads were suspended in 20 L
of assay dilution buffer, 10 L of substrate peptide
(500 M peptide AKRRRLSSLRA), 10 L of in-
hibitor mixture, and 10 L of radioactive adenosine
triphosphate (ATP) mixture (i.e., 75 mM MgCl2,
500 M ATP, and 10 Ci of [-32P]ATP) and in-
cubated for 10 minutes at 30 °C. Aliquots of 25 L
were spotted onto P81 phosphocellulose paper
squares (Upstate Biotechnology) and washed three
times with 0.75% phosphoric acid and once with
acetone to remove unreacted [-32P]ATP. The
amount of radioactive product, which remains ab-
sorbed to the paper squares, was measured in an
LS6500 scintillation spectrometer (Beckman
Coulter, Inc., Fullerton, CA).
Growth Inhibition by Rapamycin
We plated 104 cells into each well of 96-well
microtiter plates. The next day, serial dilutions of
rapamycin (Calbiochem Corp., La Jolla, CA) were
added. After incubation at 37 °C for 70 hours, the
medium was replaced with fresh drug-free medium,
and the cells were allowed to recover overnight.
Growth inhibition was measured by use of the col-
orimetric MTT (i.e., 3-[4,5-dimethylthiazol-2-yl]-
2,5-diphenyl tetrasodium bromide) test (Chemicon
International, Inc., Temecula, CA). All experiments
were performed in triplicate, and the results were
expressed as percent inhibition relative to control
cultures without rapamycin.
Immunohistochemistry
The expression of S6K in primary breast tumors
was analyzed by the use of immunohistochemistry
to the tissue microarray that contained 612 paraffin-
embedded primary breast cancer specimens. Analy-
sis of 167 was uninformative because of missing or
unrepresentative tumor samples in the array section
or failure of the analysis. A standard indirect immu-
noperoxidase protocol with 3,3-diaminobenzidine
as a chromogen was used for immunohistochemistry
(ABC-Elite; Vector Laboratories, Inc., Burlingame,
CA). Polyclonal anti-p70S6k antibody was used for
detection of S6K (1 : 5000 dilution in PBS contain-
ing 1% bovine serum albumin and 0.1% Triton
X-100). A high-temperature (20 minutes in a pres-
sure cooker) treatment procedure with Antigen Un-
masking Solution (Vector Laboratories, Inc.) was
used to enhance the staining. The primary antibody
was omitted for negative controls. S6K staining of
cytoplasm was subjectively scored into four groups:
negative (no staining), weak, moderate, or strong
staining. For statistical analyses, the data were com-
bined into two groups: low expression (negative or
weak staining) and high expression (moderate or
strong staining).
Statistical Analyses
The relationship of S6K amplification to clinico-
pathologic parameters and the association between
S6K amplification and S6K expression were ana-
lyzed by use of Fisher’s exact test. The survival
curves were estimated by Kaplan–Meier analysis.
The prognostic significance of amplification of S6K
and HER-2 was analyzed by use of the log-rank test.
All P values are two-sided.
RESULTS
cDNA Microarray Analyses
Our search for amplified DNA se-
quences in breast cancer was based on
results from CGH, which maps amplified
DNA sequences on metaphase chromo-
somes. In CGH, fluorescently labeled test
and control DNAs are hybridized to nor-
mal metaphase chromosomes, and the
fluorescence intensities and their ratios
are quantitated.
One of the most prominent amplifica-
tion sites in the MCF-7 cells is localized
at 17q23 (Fig. 1, A and B). We used a
cDNA microarray that contained 4209
clones to evaluate expression levels in
MCF-7 cells relative to those in normal
mammary epithelial cells. To better visu-
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alize the relationship between increased
copy number and increased expression
levels of genes along chromosome 17, we
displayed the data from our cDNA micro-
array analyses according to the clones’
chromosomal positions.
Fig. 1 illustrates the comparison of a
CGH copy number ratio profile for chro-
mosome 17 (panel A) with the distribu-
tion of the expression ratios for genes
along chromosome 17, arranged from
17pter to 17qter (panel D). The largest
peak in the cDNA microarray profile (Fig.
1, D) corresponds to an expressed se-
quence tag (EST) (image clone identifica-
tion No. 133432). This clone showed a
higher MCF-7-to-normal expression ratio
(8.4) than any other evaluable cDNA
clone in the cDNA microarray experiment
(Fig 1, C, and inset). This EST belongs to
a UniGene cluster Hs.124943 (25) located
at 17q23 by radiation hybrid mapping (at
369 cR) (21). Subsequent sequencing and
extension of the cDNA clones in this Uni-
Gene cluster (Forozan F, Kallioniemi
O-P: unpublished observations) indicated
that this UniGene represented the 3 un-
translated region of the ribosomal protein
S6K. The localization of S6K to 17q23
was confirmed by FISH to normal meta-
phase chromosomes (Fig. 1, E). Since
S6K is an important signaling molecule
involved in the transition from G1 to S
phase of the cell cycle, we explored fur-
ther the role of S6K as a possible ampli-
fication target gene.
S6K Copy Number, Expression, and
Enzymatic Activity in Breast Cancer
Cell Lines
The S6K gene copy number was ana-
lyzed in seven breast cancer cell lines by
interphase FISH. Cell line MCF-7 showed
at least a 10-fold amplification (Fig. 1, F),
as did cell lines KPL-1 and ZR-75-1wt
(data not shown). In other experiments for
which the data are not shown, cell line
Sum-52 showed a twofold amplification,
cell line BT-474 showed at least a five-
fold amplification, and cell lines HBL-
100 and MDA-436 showed no increase in
S6K copy number.
Expression of S6K mRNA and protein
was studied by northern and western blot
analyses. Northern blot analysis revealed
major transcripts with molecular sizes of
2.5 and 6.0 kilobases (Fig. 2, A), consis-
tent with the results of Reinhard et al.
(26). In the four cell lines that showed at
least a fivefold increase in S6K copy
number, expression of both of these tran-
scripts was increased eightfold to 20-fold
(relative to cell lines with no amplifica-
tion). Western blot analysis of five cell
lines revealed bands with apparent mo-
lecular masses of 70 and 85 kilodaltons,
which correspond to the two known iso-
forms of S6K protein (27). Increased ex-
pression of both isoforms was seen in
Fig. 1. Comparison of complementary DNA (cDNA) microarray data on the MCF-7 breast cancer cell line
with comparative genomic hybridization (CGH) results. Panel A: CGH copy number ratio profile for
chromosome 17. Normal metaphase chromosomes were hybridized with fluorescently labeled MCF-7 DNA
and normal placental DNA. The fluorescence intensities were measured along chromosome 17, and their
ratios (DNA sequence copy number in MCF-7 cells/copy number in normal tissue) were calculated. The
average copy number ratio from 10 chromosomes, aligned with the chromosome ideogram, is shown in blue,
with 95% confidence intervals in orange. The horizontal black line represents a ratio of 1.00; green, a ratio
of 1.15; and red, a ratio of 0.85. The green bar at the bottom of the figure indicates the region of
chromosome 17 with increased copy number in MCF-7 cells. Panel B: A computer-generated image of
chromosome 17 from a CGH experiment of MCF-7 cells, aligned with the chromosome 17 ideogram and
graph in panel A. Fluorescent images corresponding to the MCF-7 DNA and placental DNA were acquired
separately by the use of a Zeiss fluorescence microscope, displayed in pseudo-colors, and overlaid. The
green color indicates amplification of MCF-7 DNA at the corresponding location in the chromosome. The
red color indicates hybridization from the placental DNA. Panel C: A computer-generated cDNA micro-
array image of 4209 clones. The microarray was hybridized separately with Cyanine5–deoxyuridine tri-
phosphate (dUTP)-labeled MCF-7 cDNA and Cyanine3–dUTP-labeled normal mammary cDNA as de-
scribed in the “Methods” section. The fluorescent images from the two hybridizations were recorded
separately with a confocal microscope. The MCF-7 cDNA image was assigned a red color and the normal
mammary cDNA image a green color to form a pseudo-color image. Spots that appear red denote clones
that were more highly expressed in MCF-7 cells than in normal breast tissue, and spots that appear green
denote clones that were more highly expressed in normal breast tissue than in MCF-7 cells. Inset: an
enlarged image of the spot that had the highest red-to-green ratio of all clones on the array. Panel D:
Distribution of expression ratios for genes along chromosome 17. The red to green ratios for 135 genes
mapping to chromosome 17 were calculated from a cDNA microarray (panel C) and are shown in alignment
with the chromosome 17 ideogram from 17pter to 17qter according to their radiation hybrid map positions
in centiRays (cR). The peak at 369 cR corresponds to the enlarged inset image in panel C (highest level of
expression of all clones on the array). Panel E: Fluorescence in situ hybridization (FISH) of the Spectrum-
Orange-labeled DNA probe for ribosomal protein S6 kinase (S6K) to normal chromosome 17. The image
was produced by the use of a Zeiss fluorescence microscope equipped with a 63× objective. The red color
indicates the specific hybridization signals at 17q23, and the blue color indicates the chromosomal DNA
counterstain. The image is aligned with those in panels A and B. Panel F: FISH of the SpectrumOrange-
labeled DNA probe for S6K to MCF-7 interphase nucleus. The image was produced as in panel E. The red
color indicates the specific hybridization signals of the S6K probe, and the blue color indicates the nuclear
DNA counterstain.
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three cell lines with S6K amplification
(Fig. 2, B).
The S6K protein is activated by phos-
phorylation on multiple sites (28,29). We,
therefore, studied whether the increased
expression of S6K protein would also
lead to increased enzymatic activity.
When compared with the average enzy-
matic activity in lysates of HBL-100 and
MDA-436 (cell lines with neither ampli-
fication nor overexpression), the activity
observed in lysates from four cell lines
with S6K amplification and overexpres-
sion ranged from threefold (cell line
BT-474) to 15-fold (cell line KPL-1) (Fig.
2, C).
Growth inhibition by rapamycin,
which blocks the phosphorylation of S6K
(28), was studied in six cell lines. Over
the range of rapamycin concentrations
used (0.01–100 nM), all cell lines showed
concentration-dependent growth inhibi-
tion, regardless of their amplification sta-
tus (data not shown).
S6K Amplification and Protein
Expression in Primary Breast Cancers
by Tissue Microarrays and
Clinicopathologic Associations
We applied FISH analysis on tumor
tissue microarrays to evaluate the ampli-
fication of the S6K gene in vivo in 668
informative primary breast tumors (Fig. 3,
A). Fifty-nine tumors (8.8%) showed am-
plification of S6K (Fig. 3, B). The S6K
protein expression was analyzed in a sub-
set of 445 tumors by use of immunohis-
tochemistry. Fig. 3, C and D, illustrates
tumor samples with no S6K expression or
high S6K expression, respectively. Mod-
erate or strong cytoplasmic staining was
seen in 69 primary tumors (15.6%). There
was a statistically significant association
between S6K amplification and high S6K
expression (P  .0004), with 41.2% (14/
34) of the amplified tumors exhibiting
high S6K expression.
No statistically significant association
was seen between S6K amplification and
the age of the patient, tumor size, lymph
node status, histologic grade, or the pres-
ence of estrogen or progesterone recep-
tors (data not shown). However, patients
with S6K amplification had a statistically
significantly (P  .0021) worse survival
than patients without S6K amplification
(Fig. 4, A). A similar, statistically signifi-
cant (P  .0083) prognostic relationship
was also found with high S6K expression
(Fig. 4, B).
Since amplification of the HER-2 on-
cogene (located on the same chromosome
at 17q12) is also associated with poor
prognosis in breast cancer (30), we ana-
lyzed whether S6K showed prognostic
significance irrespective of HER-2. An
adjacent section from the tissue microar-
ray was hybridized with a probe for HER-
2, which showed amplification in 106
(17.4%) of 610 informative cases. Ampli-
fication of both S6K and HER-2 was seen
in 27 (4.4%) of the 610 cases, whereas
S6K was amplified alone in 30 cases
(4.9%). Patients with tumors showing
both S6K and HER-2 amplifications had a
statistically significantly (P  .0001)
worse prognosis than those with no am-
plification or amplification of only one of
the genes (Fig. 4, C).
DISCUSSION
Genomic DNA amplifications are
common in breast cancer and affect a
number of distinct chromosomal sites. At
each amplification site, multiple genes
may confer a clonal growth advantage to
the cancer cells. Such genes could be
promising targets for developing diagnos-
tic, prognostic, and therapeutic ap-
proaches for breast cancer. This concept
has been best demonstrated for the HER-2
gene [see (30) for a recent review], which
originally was found to be amplified in
neuroblastomas and subsequently was
shown to be associated with poor progno-
sis in breast cancer. More than 10 years
after these initial discoveries, treatment of
HER-2-positive breast cancers with the
monoclonal antibody Herceptin is now
available (30).
To rapidly identify putative target
genes for other genomic amplifications
detected in cancer by CGH, we performed
a parallel analysis of gene expression
changes by use of cDNA microarrays in
the MCF-7 breast cancer cell line and nor-
mal mammary gland tissue. The sensitiv-
ity of our cDNA microarray approach has
been described in detail previously
Fig. 2. Ribosomal protein S6 kinase (S6K) messenger
RNA (mRNA) and protein expression and kinase ac-
tivity in breast cancer cell lines. Panel A: Total RNA
from breast cancer cell lines HBL-100, MDA-436,
Sum-52, BT-474, KPL-1, ZR-75-1wt, and MCF-7 was
analyzed for expression of ribosomal protein S6K
mRNA by northern blot analysis as described in the
“Methods” section. The sizes (in kilobases, kb) of the
major transcripts (2.5 kb and 6.0 kb) were estimated by
comparison to a size standard. The membrane was re-
hybridized with a probe complementary to glyceralde-
hyde-3-phosphate dehydrogenase (GAPDH) mRNA as
a control to confirm equal loading of RNA in all seven
lanes. Panel B: Expression of S6K protein by cell lines
MDA-436, HBL-100, ZR-75-1wt, KPL-1, and MCF-7
was measured by western blot analysis by use of anti-
p70S6k antibody as described in the “Methods” section.
The sizes (in kilodaltons, kDa) of the major products
(70 kDa and 85 kDa) were estimated by comparison to
a size standard. The membrane was restained with anti-
tubulin antibody as a control for equal loading of pro-
tein in all five lanes. Panel C: S6K activity in breast
cancer cell lines HBL-100, MDA-436, BT-474, KPL-1,
ZR-75-1wt, and MCF-7. Cell lysates were incubated
with anti-p70S6k antibody, and the immunocomplex
was adsorbed to protein A–agarose and assayed for
phosphotransferase activity (pMol phosphate trans-
ferred per minute) as described in the “Methods” sec-
tion. Error bars are 95% confidence intervals.
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(18,22). In earlier experiments, we were
able to detect overexpression of several
genes shown to be expressed in MCF-7,
including CDK4, CAS, MYBL, and
PCNA (Forozan F, Mahlama¨ki EH,
Monni O, Chen Y, Veldman R, Jiang Y,
et al.: unpublished data). In separate con-
trol experiments, we have also been able
to reliably detect expression of rare tran-
scripts, such as that of the estrogen recep-
tor (data not shown).
The most highly overexpressed gene in
the MCF-7 cells was an EST correspond-
ing to the ribosomal protein S6K, a gene
mapping to 17q23, a chromosomal region
that harbors the most prominent amplifi-
cation site in the MCF-7 cell line. Based
on its biologic role, S6K represents an
ideal candidate for a gene whose activa-
tion by amplification could contribute to
oncogenesis. The S6K protein is rapidly
activated in response to various mitogenic
stimuli, such as growth factors (e.g., epi-
dermal growth factor and platelet-derived
growth factor), cytokines, and oncogene
products (28,31,32). S6K regulates protein
synthesis, translation of specific mRNA
species, and progression from the G1 to
the S phase of the cell cycle (28,32,33).
We observed high-level amplification
of the S6K gene in all four of the cell lines
with 17q23 amplifications that we exam-
ined. We also observed that the levels of
mRNA and protein expression were often
higher than those anticipated from the
level of DNA amplification and that S6K
activity was increased in all cell lines that
showed S6K gene amplification. These
observations support the hypothesis that
the S6K gene is an amplification target
gene in breast cancer cell lines.
Although 17q23 amplifications are de-
tected by CGH in both breast cancer cell
lines and uncultured primary breast tu-
mors (4–7), it is important to validate any
data from cell line model systems in clini-
cal specimens. The tissue microarray
technology (14) provides an ideal method
for rapid in vivo analysis of candidate
cancer genes in a large series of patient
specimens. S6K gene amplification and
protein expression were seen in 8.8% and
15.6%, respectively, of breast cancer
specimens. Statistically significant asso-
ciations were found between gene ampli-
fication or protein expression and poor
prognosis of patients. These results sug-
gest that S6K amplification is character-
istic of aggressive breast cancers. In more
than half of the tumors, S6K was ampli-
fied irrespective of HER-2, a known in-
dicator of poor prognosis in breast cancer
(30). Co-amplification of both of these
genes implied a much worse prognosis
than did amplification of either one alone.
A recent study (34) also supports the
role of S6K as a possible target gene for
amplification of 17q23 in breast cancer.
Couch et al. (34) found amplification of
S6K in two of 14 patient specimens
evaluated. Our results, which are based on
samples from a large number of patients,
indicate that additional clinical studies are
warranted to explore the role of S6K am-
plification both as an independent prog-
nostic indicator and as a modifier of dis-
ease progression (such as response to
Herceptin therapy) in patients with tu-
mors in which HER-2 is amplified.
Inhibition of the increased S6K activ-
ity in cancer cells with 17q23 amplifica-
tion could provide an attractive target for
therapeutic intervention. Our results indi-
cate that growth inhibition by rapamycin,
a known inhibitor of S6K activity, was
not appreciably different between cell
lines with increased S6K activity and
those with no S6K involvement. This ob-
servation may indicate that rapamycin is
not a sufficiently specific inhibitor, since
it also influences a wide variety of other
cellular functions such as induction of ap-
optosis and inhibition of several cyclins
Fig. 3. Analysis of ribosomal protein S6 kinase (S6K) amplification and ex-
pression in primary breast tumors. Panel A: A hematoxylin–eosin-stained sec-
tion from a tissue microarray containing 612 primary breast cancer specimens.
Panel B: Fluorescence in situ hybridization analysis. The tissue microarray was
hybridized with a SpectrumOrange-labeled ribosomal protein S6 kinase (S6K)-
specific probe and a SpectrumGreen-labeled probe for the chromosome 17
centromere, as described in the “Methods” section. The image of a represen-
tative tissue sample was produced by the use of a Zeiss fluorescence microscope
equipped with a 63× objective. The red spots indicate the S6K-specific hy-
bridization signals, and the green spots indicate the chromosome 17 centro-
mere-specific hybridization signals. Panels C and D: Immunohistochemical
detection of S6K protein. The tissue microarray was incubated with polyclonal
anti-p70S6k antibody, as described in the “Methods” section to give a brown
precipitate that corresponds to the presence of S6K protein. Panel C: one
representative tissue sample that shows no expression of S6K. Panel D: one
representative tissue sample that shows high-level expression of S6K. The scale
bar indicates the diameter of the tissue samples.
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(28,35–37). Therefore, studies with more
specific inhibitors of S6K activity are
warranted. It is also possible—and even
likely—that S6K is not the only gene af-
fected by the 17q23 amplifications and
that simultaneous activation of several
genes at 17q23 could contribute to cancer
progression. Our cDNA microarray
analysis was done on 4209 clones that did
not represent a complete set of genes from
a particular chromosomal region. The use
of focused cDNA microarrays that in-
clude more genes from the very gene-rich
17q23 region will allow a more compre-
hensive analysis of the molecular conse-
quences of the 17q23 amplifications and
perhaps highlight additional overex-
pressed genes.
Our results illustrate how the combina-
tion of CGH information with cDNA
and tissue microarray analyses can be
used to identify amplified and over-
expressed genes and to evaluate the
clinical implications of such genes and
genomic rearrangements. cDNA micro-
arrays are now widely used to identify
differentially expressed genes in human
cancer (38). CGH information on geno-
mic copy number provides a new param-
eter to take into account when interpret-
ing gene expression information from
thousands of cDNA clones and may
help to identify the most important tar-
gets first. Focused high-throughput analy-
sis of hundreds of clinical samples by
use of tissue microarray technology
complements these genome-screening
tools and provides information on genes
that are likely to be important for can-
cer development and progression in pa-
tients.
Our analyses imply that the S6K gene
is likely to be an important—but perhaps
not the only—target gene involved in the
17q23 amplifications in breast cancer.
S6K amplification is characteristic of ag-
gressive types of breast cancer, and detec-
tion of S6K amplification in conjunction
with HER-2 amplification may provide
more prognostic information than either
one alone. Further research is required
both on the role of S6K and on the pos-
sible presence of other overexpressed
genes in this amplicon.
Fig. 4. Kaplan–Meier analysis of breast cancer-specific survival.
Panel A: Survival according to amplification (ampl) of ribosomal
protein S6 kinase (S6K). At 2 years after diagnosis, breast cancer-
specific survival was 80.6% (95% confidence interval [CI]  65.4%–
95.8%) for patients with S6K amplification and 95.6% (95% CI 
93.2%–98.0%) for patients without S6K amplification. At 4 years,
breast cancer-specific survival was 59.2% (95% CI  32.5%–85.9%)
for patients with S6K amplification and 84.6% (95% CI  79.7%–
89.5%) for patients without S6K amplification. At 6 years, breast
cancer-specific survival was 59.2% (95% CI  22.8%–95.6%) for
patients with S6K amplification and 78.4% (95% CI  71.3%–
85.5%) for patients without S6K amplification. Panel B: Survival
according to S6K protein expression. At 2 years after diagnosis, breast
cancer-specific survival was 86.0% (95% CI  76.9%–95.1%) for
patients with high S6K expression and 95.1% (95% CI  92.7%–
97.5%) for patients with low S6K expression. At 4 years, breast can-
cer-specific survival was 69.9% (95% CI  55.5%–84.3%) for pa-
tients with high S6K expression and 86.1% (95% CI  81.5%–
90.7%) for patients with low S6K expression. At 6 years, breast
cancer-specific survival was 65.4% (95% CI  45.5%–85.3%) for
patients with high S6K expression and 79.7% (95% CI  73.0%–
86.4%) for patients with low S6K expression. Panel C: Survival
according to amplification of S6K and HER-2. At 2 years after diag-
nosis, breast cancer-specific survival was 72.7% (95% CI  43.6%–
100%) for patients with amplification of both S6K and HER-2, 87.2%
(95% CI  76.0%–98.4%) for patients with either S6K or HER-2
amplification, and 96.5% (95% CI  94.1%–98.9%) for patients with
no amplification. At 4 years, breast cancer-specific survival was
40.9% (95% CI  0%–89.1%) for patients with amplification of both
S6K and HER-2, 71.2% (95% CI  53.4%–89.0%) for patients with
either S6K or HER-2 amplification, and 88.7% (95% CI  83.9%–
93.5%) for patients with no amplification. At 6 years, breast cancer-
specific survival was 40.9% (95% CI  0%–96.5%) for patients with
amplification of both S6K and HER-2, 61.1% (95% CI  36.4%–
85.8%) for patients with either S6K or HER-2 amplification, and
83.0% (95% CI  75.9%–90.1%) for patients with no amplification.
Below each graph is the total number of patients at risk at various
time points. Two-sided P values were calculated by the log-rank test.
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